LTZ Therapeutics Receives FDA Clearance to Begin Clinical Evaluation of LTZ-232 for Advanced Metastatic Colorectal Cancer and Other Solid Tumors LTZ Therapeutics, a clinical-stage biotechnology company focused on developing next-generation cancer immunotherapies, has announced that the U.S. Food and Drug…
Uniquity Bio Strengthens Executive Leadership with Appointment of Matthew Hartzell as Chief Financial Officer Uniquity Bio, a clinical-stage biotechnology company dedicated to developing innovative therapies for immune-mediated and inflammatory diseases, has announced the appointment of Matthew Hartzell as its new…
Genmab Wins European Commission Approval for TEPKINLY® Combination Genmab A/S has announced that the European Commission (EC) has granted marketing authorization for TEPKINLY® (epcoritamab) in combination with lenalidomide and rituximab (R2) for the treatment of adult patients with relapsed or…
PharmaEssentia Receives Health Canada Approval for BESREMi® to Treat Adults with Polycythemia Vera PharmaEssentia Corporation, a Taiwan-based global biopharmaceutical company specializing in the development of innovative biologic therapies for hematology and oncology, has announced that its wholly owned subsidiary, FORUS…
Novartis Secures EU Approval for Itvisma® in SMA Novartis has announced that the European Commission (EC) has granted approval for Itvisma® (onasemnogene abeparvovec) for the treatment of children aged two years and older, adolescents, and adults living with 5q spinal…
Visby Medical Receives FDA Clearance for First At-Home Multi-Viral PCR Test for COVID-19 and Influenza Visby Medical, a company focused on developing rapid molecular diagnostics for use at home, has announced that the U.S. Food and Drug Administration (FDA) has…
PeptiDream Strengthens Executive Leadership Team with Three New Executive Vice Presidents to Accelerate Global Growth PeptiDream Inc., a publicly traded biopharmaceutical company headquartered in Kawasaki, Japan, has announced the appointment of three new Executive Vice Presidents as part of its…
Genentech Reports Positive Phase III Krascendo 1 Results Demonstrating Divarasib Improves Survival in Previously Treated KRAS G12C Non-Small Cell Lung Cancer Genentech, a member of the Roche Group, has announced positive topline results from its pivotal Phase III Krascendo 1…
Rezon Bio Appoints Dr. Hubert Scholze as Chief Business Officer to Drive Global Growth and Strengthen Biologics CDMO Capabilities Rezon Bio, a science-driven European contract development and manufacturing organization (CDMO) specializing in biologics, has announced the appointment of Dr. Hubert…
Croma-Pharma Secures FDA Approval for Obagi saypha® ChIQ™ to Expand Facial Aesthetic Treatment Options in the U.S. Croma-Pharma has reached another significant milestone in its global growth strategy with the U.S. Food and Drug Administration (FDA) approving Obagi saypha® ChIQ™,…
Hengrui’s Heng Yi® Approved in China for Dry Eye Disease Treatment Hengrui Pharma and Novaliq GmbH have announced that China’s National Medical Products Administration (NMPA) has approved Heng Yi® (0.1% cyclosporine ophthalmic solution) for the treatment of patients with dry…
Novocure Secures CE Mark for Optune Pax in Locally Advanced Pancreatic Cancer Novocure has achieved a significant regulatory milestone after receiving the CE (Conformité Européenne) Mark for Optune Pax®, authorizing the device for the treatment of adult patients with locally…